Prostate Cancer | Specialty

Dr. Kearns on Choosing Treatment for Patients With Prostate Cancer

October 30th 2018

James Kearns, MD, assistant professor of urology, Levine Cancer Institute, discusses factors to consider when choosing treatment for a patient with prostate cancer.

Darolutamide Improves MFS in Phase III Nonmetastatic CRPC Trial

October 25th 2018

Darolutamide significantly improved metastasis-free survival versus placebo in patients with nonmetastatic castration-resistant prostate cancer enrolled in the phase III ARAMIS trial.

Recent Approvals Move Needle for Nonmetastatic CRPC

October 23rd 2018

Deborah A. Bradley, MD, discusses how recent clinical trials have impacted patients with nonmetastatic castration-resistant prostate cancer and what the future holds for them.

Dr. Burgess on the Synergy Between Abiraterone and ADT in Prostate Cancer

October 23rd 2018

Earle Burgess, MD, associate professor of medicine, Levine Cancer Institute, discusses the synergy between abiraterone acetate (Zytiga) and androgen deprivation therapy (ADT) in prostate cancer.

Dr. Parker on the Role of Radiotherapy in Newly Diagnosed Prostate Cancer

October 22nd 2018

Chris Parker, MD, consultant clinical oncologist, The Royal Marsden NHS Foundation Trust, discusses the role of radiotherapy in newly diagnosed prostate cancer.

Rucaparib Responses Reached in Nearly Half of Men With BRCA+ mCRPC

October 22nd 2018

Preliminary data from the ongoing phase II TRITON2 trial demonstrated a 44% confirmed objective response rate by investigator assessment among evaluable men with BRCA1/2-mutated metastatic castration-resistant prostate cancer who were treated with the PARP inhibitor rucaparib.

Radiotherapy Raised to New Standard in Newly Diagnosed Prostate Cancer With Low Metastatic Burden

October 21st 2018

When added to standard of care therapy, radiotherapy to the prostate improves overall survival in men newly diagnosed with metastatic prostate cancer who have a low metastatic disease burden.

ESMO 2018: Dr. Verma Sheds Light on Breast Cancer Data

October 21st 2018

ESMO 2018: Dr. Ramalingam Shares Insight on Lung Cancer Studies

October 21st 2018

ESMO 2018: Dr. Abou-Alfa Discusses Updates in GI Cancer

October 21st 2018

ESMO 2018: Dr. Cohen Reflects on Practice-Changing Data in Head and Neck Cancer

October 21st 2018

ESMO 2018: Dr. George Highlights Key Abstracts in Kidney and Prostate Cancers

October 21st 2018

ESMO 2018: Dr. Moore Speaks to Exciting PARP Inhibitor Abstracts in Ovarian Cancer

October 21st 2018

OncLive News Network On Location: In Munich Monday, October 22

October 21st 2018

OncLive News Network On Location: In Munich Sunday, October 21

October 21st 2018

OncLive News Network On Location: In Munich Saturday, October 20

October 21st 2018

Adding Radium-223 to Abiraterone Shows No Survival Advantage in mCRPC

October 20th 2018

Adding radium-223 dichloride to abiraterone acetate and prednisone did not improve survival in patients with metastatic castration-resistant prostate cancer.

Dr. Bradley on Impact of SPARTAN and PROSPER in Nonmetastatic CRPC

October 19th 2018

Deborah A. Bradley, MD, medical oncologist, Levine Cancer Institute, discusses the impact of the recently published SPARTAN and PROSPER trials in nonmetastatic castration-resistant prostate cancer.

Dr. Kearns on the Role of Surgery in High-Risk Prostate Cancer

October 19th 2018

James Kearns, MD, assistant professor of urology, Levine Cancer Institute, discusses the role of surgery in patients with high-risk prostate cancer.

Gomella Gives Update on Nonmetastatic CRPC Advances

October 19th 2018

Leonard G. Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, discusses the shifting landscape of nonmetastastic CRPC, along with other developments across the prostate cancer paradigm.